Gain Therapeutics (GANX) Competitors $1.80 +0.06 (+3.45%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.80 0.00 (0.00%) As of 04/17/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. CRVS, CRGX, CDTX, ENGN, FHTX, ESPR, OCGN, AMRN, BTMD, and SOPHShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Corvus Pharmaceuticals (CRVS), CARGO Therapeutics (CRGX), Cidara Therapeutics (CDTX), enGene (ENGN), Foghorn Therapeutics (FHTX), Esperion Therapeutics (ESPR), Ocugen (OCGN), Amarin (AMRN), biote (BTMD), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Corvus Pharmaceuticals CARGO Therapeutics Cidara Therapeutics enGene Foghorn Therapeutics Esperion Therapeutics Ocugen Amarin biote SOPHiA GENETICS Corvus Pharmaceuticals (NASDAQ:CRVS) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Does the media refer more to CRVS or GANX? In the previous week, Gain Therapeutics had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 2 mentions for Gain Therapeutics and 0 mentions for Corvus Pharmaceuticals. Gain Therapeutics' average media sentiment score of 0.59 beat Corvus Pharmaceuticals' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Corvus Pharmaceuticals Neutral Gain Therapeutics Positive Which has more risk and volatility, CRVS or GANX? Corvus Pharmaceuticals has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Does the MarketBeat Community favor CRVS or GANX? Corvus Pharmaceuticals received 255 more outperform votes than Gain Therapeutics when rated by MarketBeat users. However, 73.08% of users gave Gain Therapeutics an outperform vote while only 62.08% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes29362.08% Underperform Votes17937.92% Gain TherapeuticsOutperform Votes3873.08% Underperform Votes1426.92% Do institutionals & insiders believe in CRVS or GANX? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 11.7% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings and valuation, CRVS or GANX? Gain Therapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.97-3.34Gain Therapeutics$50K1,000.33-$22.27M-$0.92-1.96 Is CRVS or GANX more profitable? Corvus Pharmaceuticals' return on equity of -70.71% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Gain Therapeutics N/A -203.91%-128.05% Do analysts recommend CRVS or GANX? Corvus Pharmaceuticals presently has a consensus price target of $15.67, indicating a potential upside of 383.54%. Gain Therapeutics has a consensus price target of $8.20, indicating a potential upside of 355.56%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Corvus Pharmaceuticals is more favorable than Gain Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryCorvus Pharmaceuticals and Gain Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.02M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-1.646.8921.8017.78Price / Sales1,000.33231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book1.865.916.443.97Net Income-$22.27M$142.72M$3.21B$247.65M7 Day Performance6.95%4.38%2.85%1.80%1 Month Performance-24.37%-12.76%-8.64%-6.98%1 Year Performance-42.86%-9.69%11.38%1.34% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics3.0427 of 5 stars$1.80+3.4%$8.20+355.6%-43.4%$50.02M$50,000.00-1.6420Gap UpCRVSCorvus Pharmaceuticals2.4673 of 5 stars$3.03+1.7%$15.67+417.1%+138.2%$206.45MN/A-3.2630Gap DownCRGXCARGO Therapeutics2.6164 of 5 stars$4.46+4.7%$15.00+236.3%-76.2%$205.39MN/A-1.05116CDTXCidara Therapeutics4.0612 of 5 stars$18.74+3.0%$39.14+108.9%+34.6%$205.26M$1.28M-0.7390Analyst UpgradeShort Interest ↑ENGNenGene3.1006 of 5 stars$4.00flat$25.22+530.6%-74.6%$203.91MN/A-6.9031Analyst RevisionFHTXFoghorn Therapeutics2.2315 of 5 stars$3.59+4.1%$13.17+266.8%-34.3%$199.65M$22.60M-1.87120ESPREsperion Therapeutics3.6775 of 5 stars$1.00-2.0%$6.58+558.9%-48.4%$197.67M$332.31M-1.56200Analyst ForecastOCGNOcugen1.2958 of 5 stars$0.67-2.8%$6.33+843.4%-52.8%$196.03M$4.06M-3.7380AMRNAmarin0.2509 of 5 stars$9.47+1.8%N/A-50.3%$194.46M$228.61M-105.22360Analyst ForecastGap DownHigh Trading VolumeBTMDbiote3.3798 of 5 stars$3.53-3.3%$8.00+126.6%-40.2%$193.13M$197.19M13.58194Positive NewsSOPHSOPHiA GENETICS1.6168 of 5 stars$2.89+0.3%$6.80+135.3%-41.6%$192.73M$65.17M-2.65520Gap Up Related Companies and Tools Related Companies Corvus Pharmaceuticals Alternatives CARGO Therapeutics Alternatives Cidara Therapeutics Alternatives enGene Alternatives Foghorn Therapeutics Alternatives Esperion Therapeutics Alternatives Ocugen Alternatives Amarin Alternatives biote Alternatives SOPHiA GENETICS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GANX Stock Free GANX Stock Alerts